Literature DB >> 7899262

Allosteric effects of the alkane-bis-ammonium compound W84 and of tacrine on [3H]pirenzepine binding at M1-receptors in rat cerebral cortex.

K Mohr1, C Tränkle.   

Abstract

The bis-quaternary W84, hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)-ammonium bromide], is a potent allosteric modulator of M2-cholinoceptors. In this study we aimed at quantifying its allosteric effect on the dissociation of [3H]pirenzepine from M1-cholinoceptors in rat cerebral cortex and to measure the effects on association and equilibrium binding of [3H]pirenzepine. For sake of comparison tacrine was included which is known to be a potent allosteric modulator of [3H]pirenzepine binding to M1-receptors. Under control conditions (3 mM MgHPO4, 50 mM Tris-HCl, pH 7.4, 23 degrees) [3H]pirenzepine binding was characterized by KD = 5 nM and Bmax = 965 fmol/mg membrane protein, the rate constants amounting to k+1 = 5.0 microM-1 x min-1 and k-1 = 0.031 min-1. W84 and tacrine reduced [3H]pirenzepine binding concentration-dependently with IC50-values of 1.9 microM and 2.6 microM, respectively. [3H]pirenzepine association was inhibited by the compounds with EC50,ass = 1.8 microM for W84 and EC50,ass = 2.4 microM for tacrine. The concentrations reducing the dissociation rate by 50% amounted to EC50,diss = 21 microM for W84 and to EC50,diss = 54 microM for tacrine. Compared with W84, the dose-reponse curves of tacrine for the investigated effects were significantly steeper. In conclusion, WS84 affected [3H]pirenzepine binding to M1-receptors allosterically with a higher potency than tacrine but probably by a different mechanism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7899262     DOI: 10.1111/j.1600-0773.1994.tb00380.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  1 in total

1.  Experimental design and estimation of parameters in complex radioligand binding systems.

Authors:  C M Staschen; L D Homer
Journal:  J Pharmacokinet Biopharm       Date:  1996-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.